×
About 17,538 results

ALLMedicine™ Atopic Dermatitis Center

Research & Reviews  5,298 results

The Skin and Nose Microbiome and Its Association with Filaggrin Gene Mutations in Pedia...
https://doi.org/10.1159/000520978
Dermatology (Basel, Switzerland); van Mierlo MMF, Pardo LM et. al.

Jan 19th, 2022 - Interactions between the skin barrier, immune system, and microbiome underlie the development of atopic dermatitis (AD). To investigate the skin and nasal microbiome in relation to filaggrin gene (FLG) mutations. A cross-sectional study including ...

Body dysmorphia in common skin diseases: Results of an observational, cross-sectional m...
https://doi.org/10.1111/bjd.21021
The British Journal of Dermatology; Schut C, Dalgard FJ et. al.

Jan 19th, 2022 - Body dysmorphic disorder (BDD) is a common psychiatric disorder associated with high costs for healthcare systems as patients may repeatedly ask for different, often not effective interventions. BDD symptoms are more prevalent in patients with der...

Evaluation of adult patients with atopic dermatitis treated with dupilumab: a single-ce...
https://doi.org/10.1111/jocd.14785
Journal of Cosmetic Dermatology; Su Küçük Ö, Güneş B et. al.

Jan 18th, 2022 - Adult atopic dermatitis (AD), especially adult-onset type appears to have different clinical manifestations. Dupilumab is an IL-4 receptor antagonist used in patients with moderate and severe atopic dermatitis, aged 12 years and older and it works...

Prevalence and characteristics of atopic dermatitis among young adult females and males...
https://doi.org/10.1111/jdv.17929
Journal of the European Academy of Dermatology and Venere... Johansson EK, Bergström A et. al.

Jan 16th, 2022 - There is limited knowledge regarding prevalence and characteristics of Atopic Dermatitis (AD) among young adults in the general population. To study AD among young adults in a Swedish population-based birth cohort, with a particular focus on preva...

Expression Pattern and Immunoregulatory Roles of Galectin-1 and Galectin-3 in Atopic De...
https://doi.org/10.1007/s10753-021-01608-7
Inflammation Corrêa MP, Correia-Silva RD et. al.

Jan 16th, 2022 - The pathogenesis of atopic dermatitis (AD) and psoriasis (Ps) overlaps, particularly the activation of the immune response and tissue damage. Here, we evaluated galectin (Gal)-1 and Gal-3 levels, which are beta-galactoside-binding proteins with im...

see more →

Guidelines  9 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Considerations on biologicals for patients with allergic disease in times of the COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300800
Allergy Vultaggio A, Agache I et. al.

Jun 6th, 2020 - The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex pat...

European task force on atopic dermatitis position paper: treatment of parental atopic d...
https://doi.org/10.1111/jdv.15709
Journal of the European Academy of Dermatology and Venere... Vestergaard C, Wollenberg A et. al.

Jun 25th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) ...
https://doi.org/10.1111/jdv.14891
Journal of the European Academy of Dermatology and Venere... Wollenberg A, Barbarot S et. al.

Apr 21st, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

The microbiome in allergic disease: Current understanding and future opportunities-2017...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899886
The Journal of Allergy and Clinical Immunology; Huang YJ, Marsland BJ et. al.

Mar 5th, 2017 - PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and ...

see more →

Drugs  451 results see all →

Clinicaltrials.gov  331 results

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
https://clinicaltrials.gov/ct2/show/NCT04773600

Jan 13th, 2022 - This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or vehicle is applied once daily for 4 weeks to subjects with atopic dermatitis.

Effects of Treatments on Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT01631617

Jan 12th, 2022 - BACKGROUND: The use of antibiotics has revolutionized medicine, yet the impact of antimicrobials on the human microbiome is incompletely understood. Antimicrobial treatments, including topical and systemic antibiotics, are highly effective and are...

Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT03252340

Jan 12th, 2022 - Participants will be followed-up for adverse events on each visit. Visits will be on 6, 12, 18, 24, 30, 36, 48, 60months after treatment of ADSTEM Inj. Time perspective is both retrospective and prospective.

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.
https://clinicaltrials.gov/ct2/show/NCT04922021

Jan 11th, 2022 - This is a clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new medicine (LEO 138559) given by injection to see if it works to treat AD and what the side effects are when com...

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
https://clinicaltrials.gov/ct2/show/NCT04921969

Jan 11th, 2022 - The purpose of the study is to assess the efficacy and safety of ruxolitinib cream in children with Atopic Dermatitis. This is a randomized, double-blind, Vehicle Controlled study. Participants will be randomized 2:2:1 to blinded treatment with ru...

see more →

News  897 results

Survey: Medical Cannabis Use for Skin Conditions Lags Behind Interest, Acceptance
https://www.medscape.com/viewarticle/966921

Jan 20th, 2022 - A majority of adults support the use of medical cannabis for the treatment of skin conditions, but relatively few have actually tried such a product, according to the results of a recent survey. Almost 89% of respondents were in favor of medical c...

FDA approves two JAK-1 inhibitors for moderate to severe atopic dermatitis
https://www.mdedge.com/dermatology/article/250777/atopic-dermatitis
Doug Brunk

Jan 14th, 2022 - The Food and Drug Administration on Jan. 14 approved two oral JAK-1 inhibitors for patients with moderate-to-severe atopic dermatitis (AD) – upadacitinib and abrocitinib – making them the first oral JAK-inhibitors available for this indication in.

Hand eczema and atopic dermatitis closely linked
https://www.mdedge.com/dermatology/article/250751/atopic-dermatitis/hand-eczema-and-atopic-dermatitis-closely-linked
Doug Brunk

Jan 14th, 2022 - An estimated 10% of adults report hand eczema each year, but over one’s lifetime, about 15%-20% will experience the condition, which is more common among those with atopic dermatitis (AD), according to Jacob P. Thyssen, MD, PhD.

FDA Approves Two Oral JAK Inhibitors for Moderate-to-Severe Atopic Dermatitis
https://www.medscape.com/viewarticle/966698

Jan 14th, 2022 - The Food and Drug Administration on Jan. 14 approved two oral JAK-1 inhibitors for patients with moderate-to-severe atopic dermatitis (AD) — upadacitinib and abrocitinib — making them the first oral JAK inhibitors available for this indication in ...

Trending Clinical Topic: Atopic Dermatitis
https://www.medscape.com/viewarticle/966211

Jan 14th, 2022 - Each week, we identify one top search term, speculate about what caused its popularity, and provide an infographic on a related condition. If you have thoughts about what's trending and why, share them with us on Twitter or Facebook. Find the late...

see more →

Patient Education  29 results see all →